All News
View More
Patterns in New Formulation Approvals Suggest “Evergreening” by Drugmakars, Researchers Report

Findings in JAMA Health Forum show that new formulations were more likely for blockbuster drugs and drugs that received accelerated approval. Proxy measures of clinical usefulness and other elements of therapeutic value were not associated with new formulations.

The Gaps Impeding Transition From the Hospital to Home

Some patients aren’t getting follow-up phone calls, and others lack transportation for appointments with physicians. A new study highlights problems in post-acute care.

Cardiac Rehab Improves Stroke Recovery, Reduces Mortality

Those who participated in rehabilitation programs were less likely to die and had improved overall function, a recent study finds.

FDA Updates for the Week of May 16, 2022

In COVID-19 news, FDA expanded EUA for Pfizer/BioNTech COVID-19 booster to children 5 to 11 years and cleared first at-home combo COVID-19, RSV and flu test, but declined an EUA for the antidepressant fluvoxamine to treat COVID-19. Regulators also approved Lilly’s novel diabetes drug and Dupixent eosinophilic esophagitis, modified Dsuvia REMS program and issued a CRL for bimekizumab for psoriasis.

Hepatitis C Is Making a Comeback

Rates dipped in the 1990s, but the opioid epidemic and the contaminated needles associated with it have caused an increase in new acute cases.

Four Ways Medicare Advantage Plans Can Stay Ahead of OIG Denial Concerns

A recent HHS Office of Inspector General's report found that Medicare Advantage (MA) plans inappropriately deny prior authorization requests. With MA enrollment growing, scrutiny of MA plans and their utilization management strategies is also likely to grow, according to Alina Czekai, M.P.H., of Cohere Health. Czekai argues that artificial intelligence and machine learning can improve utilization management and prevent inappropriate denials.

Keeping Members by Making Them ’Appy: Health Plans and Wellness Apps

Florida Blue and Blue Shield of California are among the insurers curating and offering free access to wellness apps for their members.

The Biosimilars That May Compete With Humira Starting Next Year

A list of biosimilar competitors to Humira that may come on the market next year.

Humira, the biosimilars are coming, the biosimilars are coming!

Circle 2023 on your calendar. That's when as many as 11 biosimilars to Humira are headed for the U.S. market.

Official Media Partners

PBMI logo

Join the Community

an mjh life sciences brand

© 2022 MJH Life Sciences and PBMI. All rights reserved.